RAC 2.42% $1.61 race oncology ltd

IMO I think the iceberg analogy is appropriate for the following...

  1. 2,747 Posts.
    lightbulb Created with Sketch. 2436

    IMO I think the iceberg analogy is appropriate for the following reason.

    We can agreed there is information in any ASX listed company that SHs do not and should not know.
    The reasons can vary from IP protection to work in progress or a simple confidentiality clause in a contract etc.

    I am invested in a variety of different ASX listed coys and most of the expected information is for a single outcome.
    i.e. an explorer looking for a final BOA or funding to go mining.
    A biotech looking for a JV partner after a successful P1 extension trial...

    What I am saying is there is different amounts of information withheld in each coy.
    For most of my other investments we know 6/7 of the information.
    i.e. the final piece (1/7) is the bit missing.

    For Race, there is so much going on I feel we only know 1/7 of the information.
    Why? We are waiting for research reports, patent applications, clinical trials, usage approvals etc.
    i.e. most of the information is below the waterline and not seen by SHs

    I would even suggest Race themselves are yet to know all of the iceberg!
    i.e. continue the research.

    ...and as the good Dr T points out, there is a balance between continued research and commercialisation for SH value.
    Race is not going to solve every benefit of Bisantrene in treating cancer before a commercial transaction is struck.
    If Bisantrene is to become a new platform from which to treat Cancer and other ailments, this is perhaps where licencing per indication is likely the best commercial outcome for Race and its SHs. Will Big Pharma have a appetite for licencing? Who knows. Licencing is also likely the best outcome for Cancer patients because the other treatments can be developed faster and not be hidden inside a Big Pharma. However, a total buyout may be the outcome. Either way I am confident it will be life changing for most of us.

    My number one wish is for Bisantrene to be fully researched and brought to market for the benefit of every Cancer patients possible in the shortest timeframe.

    Cheers
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
(20min delay)
Last
$1.61
Change
-0.040(2.42%)
Mkt cap ! $267.8M
Open High Low Value Volume
$1.71 $1.71 $1.54 $370.9K 232.5K

Buyers (Bids)

No. Vol. Price($)
1 392 $1.58
 

Sellers (Offers)

Price($) Vol. No.
$1.61 13999 1
View Market Depth
Last trade - 16.10pm 15/05/2024 (20 minute delay) ?
Last
$1.58
  Change
-0.040 ( 6.08 %)
Open High Low Volume
$1.62 $1.65 $1.54 41933
Last updated 15.58pm 15/05/2024 ?
RAC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.